Iris Bincovich, CEO of Innocan, said: "Innocan is making meaningful progress across both its pharmaceutical and cosmetics segments, with continued sales growth and sustained profitability. We believe this continues to build on the great potential of Innocan diversified Platform: Pharma • Veterinary • Wellness and investors should be paying attention to the potential upside this company has:
Proprietary Injectable Platform- LPT-CBD enables exact dosing and ~4-week sustained release a differentiated non-opioid approach to chronic pain.
505(b)(2) Regulatory Path - FDA agreed to a 505(b)(2) abbreviated submission pending a scientific bridge, accelerating route to approval
US$271B Combined Addressable Market** - Human chronic pain (US$109B), animal pain (US$2.2B) and global beauty / personal care (US$161B) opportunity.
Animal Health Near-Term Catalyst - CVM INAD number assigned; 3-year sponsor fee waiver. ~US$1.07B U.S. dog osteoarthritis opportunity.
Cash-Generating Wellness Engine - FY25 revenues of US$26.6M at ~90% gross margins
Defensible IP & World-Class Team- 31 granted & pending patents across 8 families.
In line with our strategic priorities, we have decided to defer the Company's proposed initial public offering in the United States to a later time and focus our resources on scaling our core operations in our core markets.
FISCAL 2026 THREE MONTHS SELECT FINANCIAL RESULTS (unaudited)
*Consolidated
Revenues totaled US$6.465 million for the three months ended March 31, 2026, representing a strong sequential increase of 29.7% compared to the fourth quarter of 2025 (US$4.99 million), reflecting continued momentum across the Company's operations. On a year-over-year basis, revenues decreased 17.07% compared to the same period in the prior year.
Gross Profit totaled US$5.89 million representing a decrease of 17.2% on a reported basis for the three months ended March 31, 2026, and representing an increase of 32.97% compared to previous quarter, the last quarter of 2025 totaled $4.43.
Gross Margin remained high at 91.1% despite the decline in revenues in three months ended March 31, 2026.
Operating loss totaled US$0.786 million, representing an increase of 261.1% on a reported basis for the three months ended March 31, 2026, and representing a decrease of 14.67% compared to previous quarter, the last quarter of 2025 totaled $0.921.
(US$ in millions)
Three Months Ended31 March
Percentage
Change
